Zobrazeno 1 - 10
of 10
pro vyhledávání: '"MICHAL HRNCIARIK"'
Autor:
Kristian Brat, Monika Bratova, Jana Skrickova, Magda Barinova, Karolina Hurdalkova, Milos Pesek, Libor Havel, Leona Koubkova, Michal Hrnciarik, Jana Krejci, Ondrej Fischer, Milada Zemanova, Helena Coupkova, Martin Svaton
Publikováno v:
Thoracic Cancer, Vol 11, Iss 11, Pp 3346-3356 (2020)
Background Data regarding real‐life effectiveness of any treatment may improve clinical decision‐making. The aim of this study was to evaluate real‐life effectiveness of tyrosin‐kinase inhibitors, bevacizumab and pemetrexed as first‐line tr
Externí odkaz:
https://doaj.org/article/cbc351e845594ab6848729e0cc8a090b
Autor:
Ondrej Fiala, Milos Pesek, Jana Skrickova, Vitezslav Kolek, Frantisek Salajka, Marcela Tomiskova, Monika Satankova, Juraj Kultan, Jana Kuliskova, Martin Svaton, Michal Hrnciarik, Karel Hejduk, Renata Chloupkova, Ondrej Topolcan, Helena Hornychova, Marketa Nova, Ales Ryska, Jindrich Finek
Publikováno v:
Tumor Biology, Vol 39 (2017)
Pemetrexed is an antifolate cytostatic agent targeting several folate-dependent enzymatic pathways, widely used in the treatment of locally advanced or metastatic stage non-small cell lung cancer. Aside from the non-squamous histology, there is still
Externí odkaz:
https://doaj.org/article/a10b69b60ee9430d88da3e92872c1cd6
Autor:
Martin Svaton, Marie Drosslerova, Ondrej Fischer, Miloslav Marel, Michal Hrnciarik, Ondrej Venclicek, Petr Zuna, Michal Svoboda, Jiri Blazek, Monika Bratova, Andrea Mullerova, Bohuslava Vankova, Daniel Krejci
Publikováno v:
Translational Cancer Research. 11:3017-3023
Programmed death-ligand 1 (PD-L1) expression is a standard predictor in the selection of immunotherapy for locally advanced/advanced non-small cell lung cancer (NSCLC). However, comedication with corticosteroids or non-steroidal anti-inflammatory dru
Autor:
Miloslav, Marel, Zdenka, Chladkova, Luis Fernando, Casas Mendez, Ondrej, Venclicek, Jana, Skrickova, Ondej, Fischer, Andrea, Mullerova, Libor, Havel, Zuzana, Gyorfy, Michal, Hrnciarik, Michal, Jirousek, Jana, Krejci, Daniel, Krejci, Marcela, Buresova, Jana, Alahakoon, Michal, Svoboda, Martin, Svaton
Publikováno v:
Cancer Diagn Progn
Background/Aim: This study aimed at contributing to a better diagnosis of lung cancer by analyzing the patient’s symptoms and their linkage to other characteristics. Patients and Methods: We analyzed the data of 3,322 patients from LUCAS (LUngCAnce
Autor:
MARTIN SVATON, MARIE DROSSLEROVA, ONDREJ FISCHER, MILOSLAV MAREL, MICHAL HRNCIARIK, ONDREJ VENCLICEK, PETR ZUNA, MICHAL SVOBODA, JIRI BLAZEK, MONIKA BRATOVA, ANDREA MULLEROVA, BOHUSLAVA VANKOVA, DANIEL KREJCI
Publikováno v:
Anticancer research. 42(3)
Due to some interconnectedness at the molecular level, this study assessed the possible influence of laboratory parameters associated with systemic inflammatory environment on programmed death-ligand 1 (PD-L1) expression in non-small cell lung carcin
Autor:
MARTIN SVATON, MONIKA BRATOVA, LEONA KOUBKOVA, ONDREJ FISCHER, BOHUSLAV MELICHAR, MICHAL HRNCIARIK, DANIEL DOLEZAL, ONDREJ BILEK, JANA KREJCI, MARIE DROSSLEROVA, ZDENKA DLOUHA, JIRI BLAZEK, PETRA MAJKOVA, LUCIE BROZOVA, MAREK STASTNY
Publikováno v:
Anticancer research. 42(4)
This study compared the results of nivolumab treatment in patients with pulmonary adenocarcinomas based upon previous chemotherapeutic regimens.The data source for this retrospective study was the Czech VILP registry of patients with nivolumab-treate
Autor:
Martin, Svaton, Monika, Bratova, Ondrej, Fischer, Jana, Krejci, Leona, Koubkova, Marketa, Cernovska, Michal, Hrnciarik, Milada, Zemanova, Helena, Coupkova, Bedrich, Porzer, Daniel, Dolezal, Tana, Tuzova, Karolina, Hurdalkova, Magda, Barinova, Jana, Skrickova
Publikováno v:
Anticancer research. 41(4)
We investigated efficacy differences for afatinib versus gefitinib in non-small-cell lung cancer (NSCLC) according to epidermal growth factor receptor (EGFR) mutations.We retrospectively analysed data for 343 patients with NSCLC with performance stat
Autor:
Michal Hrnciarik, Miloslav Hronek, Petra Fikrova, Rudolf Stetina, Zdenek Zadak, Dana Hrnciarikova
Publikováno v:
Oncology Reports. 31:391-396
Lung cancer is the leading cause of cancer-related mortality in the world. Chemotherapy has been the mainstay of treatment for advanced non-small cell lung cancer (NSCLC) and platinum-based derivatives have been shown to improve overall survival. The
Autor:
Zdeněk Zadák, Miloslav Hronek, Rehacek, Jost P, Petra Fikrova, Michal Hrnciarik, Rudolf Stetina
Publikováno v:
Neoplasma. 60:413-418
Platinum-based chemotherapeutic agents induce the formation of crosslinks in DNA, which are accepted as being responsible for the cytotoxicity of these agents. In this study, we used a modification of the alkaline comet assay for detection of the pre
Autor:
Dana, Hrnciariková, Michal, Hrnciarik
Publikováno v:
Casopis lekaru ceskych. 150(6)
Spiritual life of the elderly patients is very important, but in practice the medical staff hardly thinks about the spiritual needs. According to foreign studies, a lively faith has a positive curative effect. The aim of our work was the evaluation o